DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Phase 3

Active, not recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Inclisiran sodium 300 mg

First Posted Date: 2022-05-04

Last Posted Date: 2025-03-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 608

Registration Number: NCT05360446

Locations: 🇺🇸
Heart Center Research Llc, Huntsville, Alabama, United States
🇺🇸
Alaska Heart and Vascular, Anchorage, Alaska, United States
🇺🇸
Cardiovascular Res Found, Beverly Hills, California, United States

and more 54 locations

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small Cell Lung
Colorectal Tumors
Neoplasms, Colorectal
KRAS G12C Mutant Solid Tumors
Non-Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Colorectal Carcinoma
Nonsmall Cell Lung Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: JDQ443
Drug: Ribociclib
Drug: trametinib
Biological: cetuximab

First Posted Date: 2022-05-03

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 346

Registration Number: NCT05358249

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
NYU School of Medicine, New York, New York, United States

and more 1 locations

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Phase 3

Active, not recruiting

Conditions: Sjogren Syndrome

Interventions: Biological: VAY736
Other: Placebo

First Posted Date: 2022-04-27

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 506

Registration Number: NCT05349214

Locations: 🇺🇸
Clinic of Robert Hozman, Skokie, Illinois, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Advanced Medical Research, La Palma, California, United States

and more 21 locations

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Completed

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)

Interventions: Other: KYMRIAH
Other: YESCARTA

First Posted Date: 2022-04-27

Last Posted Date: 2022-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 273

Registration Number: NCT05349201

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Phase 3

Active, not recruiting

Conditions: Sjogren Syndrome

Interventions: Other: Placebo
Biological: VAY736

First Posted Date: 2022-04-27

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 276

Registration Number: NCT05350072

Locations: 🇺🇸
Medvin Clinical Research, Van Nuys, California, United States
🇺🇸
Ochsner Health System, Baton Rouge, Louisiana, United States
🇺🇸
Metroplex Clinical Research, Dallas, Texas, United States

and more 12 locations

A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Other: ofatumumab
Other: glatiramer acetate
Other: interferon β1

First Posted Date: 2022-04-25

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 564

Registration Number: NCT05344469

Locations: 🇩🇪
Novartis Investigative Site, Weil der Stadt, Germany

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

Completed

Conditions: Plaque Psoriasis

Interventions: Other: Secukinumab

First Posted Date: 2022-04-25

Last Posted Date: 2022-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 277

Registration Number: NCT05344482

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

Phase 3

Recruiting

Conditions: Spinal Muscular Atrophy (SMA)

Interventions: Biological: onasemnogene abeparvovec

First Posted Date: 2022-04-20

Last Posted Date: 2024-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT05335876

Locations: 🇺🇸
Child Hosp Of The Kings Daughters, Norfolk, Virginia, United States
🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Other: Kesimpta

First Posted Date: 2022-04-19

Last Posted Date: 2024-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT05334472

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: LMI070

First Posted Date: 2022-04-15

Last Posted Date: 2023-07-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT05330286

Locations: 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy